| Ticker: TTNP | 1505 O'Brien Drive, Suite B | |
| Exchange: NASDAQ-Small Cap Market | Menlo Park, California 94025 | |
| Industry: Manufacturing | (415) 617-2090 |
| Type of Shares: | Common Shares | Filing Date: | ||
| U.S. Shares: | 3,200,000 | Offer Date: | 1/18/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $5.00 | |
| Primary Shares: | 3,200,000 | Offer Price: | $5.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.35 | |
| Offering Amount: | $16,000,000 | Selling: | $0.12 | |
| Expenses: | $1,200,000 | Reallowance: | $0.06 | |
| Shares Out After: | 10,269,659 |
| Manager | Tier | Phone |
| D.H. Blair & Co Inc. | Lead Manager | (212) 495-4000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/94 | 9/30/95 | 9/30/94 | 9/30/95 | ||
| Revenue: | $0.00 | $0.18 | $0.00 | Assets: | $3.40 |
| Net Income: | -$12.97 | -$8.85 | -$8.96 | Liabilities: | $8.29 |
| EPS: | -$1.86 | -$1.18 | Equity: | -$4.89 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The Company is a biopharmaceutical company engaged in the identification and acquisition of synergistic technologies, with applications in the areas of cancer, immunology, viral diseases and disorders of the central nervous system. The Company's operations are currently conducted through four operating companies: Ansan, Inc., a company engaged in the development of small molecule-based therapeutics intended for the treatment of cancer and hemaglobinopathies; Ingenex, Inc., a company engaged in gene identification and functional analysis for the discovery of novel gene-based therapeutics initially for the treatment of cancer and certain viral diseases; and Theracell, Inc., a company engaged in the development of cell-based therapeutics intended for the restorative treatment of neurological diseases and central nervous system disorders. ProNeura Inc. was recently established to conduct research and development activities relating to a polymeric implantable drug delivery technology. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay $3,750,000 principal amount of 10% promissory notes issued in the bridge financing; to repay $1,500,000 principal amount of 9% promissory notes issued by Ingenex for research and development and support of the operating companies; and for working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.